NurExone Biologic Inc. (TSXV: NRX) will present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference on September 9, 2026.

The biotechnology company, which develops exosome-based regenerative therapies, announced its participation in the event taking place in New York City from September 9 to 10, 2026.

Presentation Details

Yoram Drucker, Co-Founder, Chairman and Vice President of Strategic Development, will deliver an investor presentation and participate in one-on-one meetings with investors.

Drucker stated that NurExone is continuing preclinical development activities and preparing for potential clinical development. The company is also taking steps to support manufacturing and commercial capabilities for longer-term development.

Strategic Focus

The presentation will cover the company’s therapeutic-development activities, exosome platform, and U.S. manufacturing and commercial initiatives. NurExone aims to engage with the investment community regarding these areas.

About NurExone

NurExone is listed on the TSX Venture Exchange, OTCQB, and Frankfurt Stock Exchange. The company focuses on developing regenerative exosome-based therapies for central nervous system injuries.

Its lead product, ExoPTEN, has demonstrated preclinical data supporting clinical potential in treating acute spinal cord and optic nerve damage. The company has obtained Orphan Drug Designation to facilitate its roadmap towards clinical trials in the U.S. and Europe.

NurExone has established Exo-Top to anchor its North American activity and growth strategy. The company expects to offer solutions for quality exosomes and minimally invasive targeted delivery systems.

NurExone Biologic Inc (TSXV: NRX) will seek shareholder approval on September 15, 2026, for a share consolidation of up to 30:1. The corporate action is intended to support the company’s strategy to list on a major US stock exchange.

The Toronto and Haifa-based biotech firm announced its annual general and special meeting of shareholders will take place at 2:00 pm Toronto time. The resolution requires an affirmative vote of not less than 66⅔% of votes cast by shareholders present.

Strategic Rationale

The Board of Directors believes the consolidation is a prudent enabling step in NurExone’s broader capital markets strategy. The company is evaluating potential US capital markets alternatives, including a possible future listing of shares on a major US stock exchange.

The proposed consolidation aims to help position the company to satisfy minimum bid price or similar listing requirements that may apply in connection with a potential future listing. The Board noted that the company’s current low nominal trading price may limit its ability to satisfy those requirements without implementing the consolidation.

Yoram Drucker, Chairman of the Board, stated that shareholder approval would provide additional flexibility as the company evaluates potential US capital markets alternatives and pursues the next phase of growth.

Implementation Details

If approved, the Board will be authorized to implement the consolidation within 36 months following shareholder approval. The exact timing and final ratio will be determined by the Board, which retains full discretion not to proceed if it determines it is no longer in the best interests of the company.

Implementation is subject to acceptance by the TSX Venture Exchange (TSXV) and receipt of all other required approvals. The Board believes providing flexibility on timing and ratio allows the company to account for market conditions and trading performance prior to implementation.

Eran Ovadya, Chief Financial Officer, noted that a higher anticipated post-consolidation trading price may improve marketability and allow engagement with additional institutional investors. However, he cautioned that there can be no assurance that the consolidation will improve liquidity, marketability, or trading price.

Other Agenda Items

At the meeting, shareholders will also be asked to elect directors and re-appoint the company’s auditor. Disinterested shareholders will consider the annual re-approval of the company’s amended and restated omnibus equity incentive plan.

Dr. Lior Shaltiel, Chief Executive Officer, said the proposed consolidation is intended to support the evolution of the company’s public market profile and share structure to align with US-listed biotechnology peers.

The company cautioned that no final decision has been made to pursue any US exchange listing, file a registration statement with the US Securities and Exchange Commission, or undertake a financing. Any potential US listing remains subject to numerous conditions, including final Board approval, TSXV acceptance, and satisfaction of all applicable listing standards.